A phase I/II study of bexarotene with carboplatin and weekly paclitaxel for the treatment of patients with advanced non-small cell lung cancer | Zendy

Konstantin H. Dragnev | Zendy; Jeremy D. Whyman | Zendy; Cynthia K. Hahn | Zendy; Peter E. Kebbekus | Zendy; Sarah F. Kokko | Zendy; Sunil Bhatt | Zendy; James R. Rigas | Zendy

Open Access

A phase I/II study of bexarotene with carboplatin and weekly paclitaxel for the treatment of patients with advanced non-small cell lung cancer

Author(s) -

Konstantin H. Dragnev,

Jeremy D. Whyman,

Cynthia K. Hahn,

Peter E. Kebbekus,

Sarah F. Kokko,

Sunil Bhatt,

James R. Rigas

Publication year - 2018

Publication title -

journal of thoracic disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.682

H-Index - 60

eISSN - 2077-6624

pISSN - 2072-1439

DOI - 10.21037/jtd.2018.09.10

Subject(s) - bexarotene , carboplatin , medicine , lung cancer , paclitaxel , neutropenia , tolerability , gastroenterology , chemotherapy , pharmacology , oncology , surgery , adverse effect , cisplatin , biochemistry , chemistry , nuclear receptor , transcription factor , gene

Rexinoids demonstrate anti-proliferative differentiation-inducing activity in multiple cancer types, including NSCLC. Prior studies have shown promising results when combining rexinoids with chemotherapy. This phase I/II study evaluates the tolerability and activity of a rexinoid, bexarotene, combined with weekly paclitaxel and monthly carboplatin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research